2-[(2-piperidin-1-ylethyl)thio]quinazolin-4(3H)one | 684276-17-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-[(2-piperidin-1-ylethyl)thio]quinazolin-4(3H)one
• 英文别名: 2-((2-piperidin-1-ylethyl)thio)quinazolin-4(3H)-one；2-(2-piperidin-1-ylethylsulfanyl)-3H-quinazolin-4-one
• CAS: 684276-17-3
• 化学式: C₁₅H₁₉N₃OS
• 分子量: 289.401
• InChiKey: QEAAIHDHSHTGMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  70
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• QUINAZOLINONE-DERIVATIVES AND THEIR USE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS HAVING PARP ENZYME INHIBITORY EFFECT
  申请人：Pécsi Tudomànyegyetem

  公开号：EP1622881B1

  公开（公告）日：2010-05-26
• Quinazolinone-derivatives and their use for preparation of pharmaceutical compositions having parp enzyme inhibitory effect
  申请人：Sumegi Balazs

  公开号：US20070042935A1

  公开（公告）日：2007-02-22

  The subject of the present invention are quinazoline derivatives and their pharmaceutically acceptable salts of general formula (I), that inhibit a DNA-repairing enzyme, poly(ADP-ribose) polymerase (PARP), enabling them to be used for the preparation of pharmaceutical compositions for preventing or treating illnesses where PARP-inhibition yields a beneficial effect. In general formula (I) R 1 stands for either hydrogen or a group of general formula (a); R 2 stands for a) hydrogen or C 1-6 alkyl group, if R 1 is other than hydrogen, and b) if R 1 is hydrogen, then R 2 may be a group of general formula (b), (c) or (d). The subject of the present invention also embraces the preparation processes of the compounds described above.
• PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER
  申请人：ArQule, Inc.

  公开号：US20200155521A1

  公开（公告）日：2020-05-21

  The present application is drawn to methods of treating a cell proliferative disorder, such as a cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising at least one of Compound 1, Compound 2, and Compound 3, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, and at least one second therapeutic agent or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, wherein the cell proliferative disorder is treated.
• US7994182B2
  申请人：——

  公开号：US7994182B2

  公开（公告）日：2011-08-09